Asceneuron is a clinical stage biotech company focused on the development of orally bioavailable therapeutics for debilitating neurodegenerative disorders with high unmet medical need. The pipeline reflects our ambition to develop treatments for a wide a range of neurodegenerative diseases including orphan tauopathies, Alzheimer’s and Parkinson’s disease. Asceneuron has two clinical stage small molecule O-GlcNAcase inhibitors in development for the treatment of proteinopathies including Parkinson’s Disease, Alzheimer’s disease and related disorders. Asceneuron is a privately held company financed by a renowned syndicate of investors consisting of Sofinnova Partners, M Ventures, SR One, Johnson & Johnson Innovation – JJDC, Inc. (JJDC) and Kurma Partners. For more information, please visit www.asceneuron.com. Further information: www.asceneuron.com
Looking for a particular Asceneuron SA employee's phone or email?
The Asceneuron SA annual revenue was $6 million in 2026.
Bruno Permanne is the Senior Director, Head of Preclinical Development of Asceneuron SA.
3 people are employed at Asceneuron SA.
The NAICS codes for Asceneuron SA are [54, 541714, 541, 54171, 5417].
The SIC codes for Asceneuron SA are [873, 87].